BOSTON, February 3, 2021 – Proskauer, a leading international law firm, today announced that its client, ARCH Venture Partners has closed its ARCH Venture Fund XI, with $1.85 billion to invest in the creation and funding of early stage biotechnology companies.

ARCH will invest Fund XI in early stage biotechnology companies working on infectious disease, mental health, immunology, oncology, neurology, manufacturing, clinical trials, anti-aging medicines, genomic and biological tools, data sciences, and ways of reimagining diagnostics and therapies. ARCH continues to take a special interest in how healthcare is delivered to patients – from data collection to therapeutics manufacturing to direct patient care.

A number of ARCH-backed companies have already made, and continue to make, important contributions to the fight against COVID-19.

Proskauer has a long standing relationship with ARCH Venture Partners, having worked with them since their founding over 30 years ago. The team was led by Robin Painter, with David Jones, Emily O’Brien, Alexandria Martin and Antonio Carrera (Private Funds), Jim Poindexter and Kim Swiszcz (Tax) and Adam Scoll (ERISA).

About Proskauer

We are 725+ lawyers serving clients from 12 offices located in the leading financial and business centers in the Americas, Europe and Asia. The world’s leading organizations, companies and corporations choose us to be their representatives in their most critical situations. But more, they consider Proskauer a strategic partner to drive their business forward. We work with asset managers, major sports leagues, Fortune 500 companies, entertainment industry legends and other industry-redefining companies.